Clinical Trial for Advanced, Recurrent Ovarian Cancer
Holy Name Medical Center is conducting a clinical trial for advanced, recurrent ovarian cancer, one of the more difficult diseases to treat. The SORAYA study assesses a promising medication developed by Immunogen called mirvetuximab soravtansine, which targets and kills cancer cells that return during or within six months of platinum-based therapy.
This Phase 3 trial aims to demonstrate durable responses, better than would be expected with available therapies. Mirvetuximab soravtansine is an antibody linked to a chemotherapy drug. The antibody attaches to the recurring cancer cells and then delivers the medication to kill them.
The SORAYA study is one of 12 investigational studies, with six more in the pipeline, at Holy Name's Institute for Clinical Research involving treatments for gynecological cancers. All studies are carefully controlled and closely monitored to ensure the safety of participants.
The research team includes physician researchers, nurse practitioners and nurses who track patients throughout the process. Anyone interested in learning more about the SORAYA study or any of the other clinical trials occurring at Holy Name should call the Institute of Clinical Research at 201-541-6312.
SORAYA Study in Action
Standard chemotherapy fell short in treating Rebecka Hess' ovarian cancer – the disease returned with a vengeance. Now, she's receiving specialized medication through a clinical trial at Holy Name that is holding the cancer at bay and giving her a better quality of life.
Rebecka Hess
Grateful for Every Day and for Clinical Trials
Rebecka, a professor of veterinary medicine at the University of Pennsylvania, travels to Holy Name from her home in Philadelphia every three weeks for an infusion of mirvetuximab soravtansin. The trial medication is a chemotherapy that works by attaching to and then killing cancer cells with minimal harm to healthy cells.
She has access to this advanced treatment through the Soraya clinical trial,...
